One-year clinical outcomes after sirolimus-eluting coronary stent implantation for acute myocardial infarction in the worldwide e-SELECT registry

Journal of Interventional Cardiology
Stephen Worthleye-SELECT Investigators

Abstract

The aim was to ascertain the 1-year clinical outcomes of 1,234 patients who underwent implantations of sirolimus-eluting stents (SES) for acute myocardial infarction (MI) in the multinational e-SELECT registry. Fifteen thousand and one hundred and forty-seven patients treated with SES were entered in the e-SELECT registry, of whom 1,234 presented within <24 hours of onset of acute MI. At 1 year, the rates of major adverse cardiac events (MACE) (5.5% vs. 4.8%; P = 0.28) were similarly low in the acute and no acute MI groups. The rates of definite/probable stent thrombosis (ST) were higher in the acute MI group (2.1%vs; 0.88%, P < 0.001). ST was a strong independent predictor of death at 1 year (HR 13.4; 95% CI 5.0, 36.0; P < 0.001) and MI (HR 58.9; 95% CI 26.9, 129.1; P < 0.001). Dual antiplatelet therapy (DAPT) compliance at 6 months was 96.0% in the acute MI versus 94.5% in the no acute MI group (P = 0.03). In selected patients presenting within <24 hours of acute MI onset and highly compliant with DAPT, SES implantation was associated with similar rates of MACE, though higher rates of ST, as compared to no acute MI patients.

References

May 5, 2005·JAMA : the Journal of the American Medical Association·Marco ValgimigliUNKNOWN STRATEGY Investigators
Sep 8, 2006·The New England Journal of Medicine·Gilles MontalescotUNKNOWN STEEPLE Investigators
Sep 15, 2006·The New England Journal of Medicine·Christian SpauldingUNKNOWN TYPHOON Investigators
Sep 15, 2006·The New England Journal of Medicine·Gerrit J LaarmanMark Patterson
Feb 14, 2007·The New England Journal of Medicine·Laura MauriDonald E Cutlip
May 2, 2007·Circulation·Donald E CutlipUNKNOWN Academic Research Consortium
May 15, 2007·Journal of the American College of Cardiology·Maurizio MenichelliRoberto Violini
May 19, 2007·Arteriosclerosis, Thrombosis, and Vascular Biology·Aloke V FinnRenu Virmani
Nov 6, 2007·The New England Journal of Medicine·Stephen D WiviottUNKNOWN TRITON-TIMI 38 Investigators
Sep 26, 2008·The New England Journal of Medicine·Laura MauriSharon-Lise T Normand
Jan 17, 2009·European Heart Journal·Ph Gabriel StegUNKNOWN Global Registry of Acute Coronary Events (GRACE) Investigators
Feb 11, 2009·Circulation·Stéphane Cook, Stephan Windecker
Apr 18, 2009·Journal of the American College of Cardiology·Jochem W van WerkumJurriën M ten Berg
May 8, 2009·The New England Journal of Medicine·Gregg W StoneUNKNOWN HORIZONS-AMI Trial Investigators
Jun 23, 2009·JACC. Cardiovascular Interventions·Neville KukrejaUNKNOWN Interventional Cardiologists of the Thoraxcenter (2000 to 2005)
Oct 16, 2010·Journal of the American College of Cardiology·David R HolmesDavid J Moliterno
Jul 19, 2011·EuroIntervention : Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·Giovanni AmorosoStefan Verheye

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.